RT @DaveGennert: Serial profiling #ctDNA in stg 3 CRC offers insight into recurrence risk, by @TennaVesterman, @ClausLindbjerg, et al in @C…
Serial profiling #ctDNA in stg 3 CRC offers insight into recurrence risk, by @TennaVesterman, @ClausLindbjerg, et al in @CCR_AACR. ctDNA+ prognostic post-op, esp after adjuvant chemo (HR >50(!)). Also dynamics (fast vs slow) of ctDNA+ further predictiv
RRIDs were included in the Clinical Cancer Research paper "Circulating Tumor DNA in Stage III Colorectal Canc…" (https://t.co/fo7tb1FzGB). We appreciate the author's support of reproducibility. #accelerateopenscience #reproducibility
RT @CCR_AACR: The #liquidbiopsy paper by @TennaVesterman, @TarazonaNoelia, @amanda_fbj @ClausLindbjerg et al @AarhusUni @incliva_iis @CIBER…
RT @CCR_AACR: The #liquidbiopsy paper by @TennaVesterman, @TarazonaNoelia, @amanda_fbj @ClausLindbjerg et al @AarhusUni @incliva_iis @CIBER…
RT @CCR_AACR: The #liquidbiopsy paper by @TennaVesterman, @TarazonaNoelia, @amanda_fbj @ClausLindbjerg et al @AarhusUni @incliva_iis @CIBER…
RT @CCR_AACR: The #liquidbiopsy paper by @TennaVesterman, @TarazonaNoelia, @amanda_fbj @ClausLindbjerg et al @AarhusUni @incliva_iis @CIBER…
RT @CCR_AACR: The #liquidbiopsy paper by @TennaVesterman, @TarazonaNoelia, @amanda_fbj @ClausLindbjerg et al @AarhusUni @incliva_iis @CIBER…
RT @CCR_AACR: The #liquidbiopsy paper by @TennaVesterman, @TarazonaNoelia, @amanda_fbj @ClausLindbjerg et al @AarhusUni @incliva_iis @CIBER…
The #liquidbiopsy paper by @TennaVesterman, @TarazonaNoelia, @amanda_fbj @ClausLindbjerg et al @AarhusUni @incliva_iis @CIBERONC @AalborgUniNyt describes the use of #ctDNA to assess adjuvant therapy efficacy and detect early relapse of #colorectalcancer.
Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences https://t.co/kMloTq1skl
Henriksen et al assess the predictive power of postoperative ctDNA detection and the benefits of serial analysis: assessing adjuvant chemotherapy efficacy, early relapse detection, and ctDNA growth rates in stage III colorectal cancer patients. https://t.c
Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences https://t.co/FORAxcl7Xz
RT @pashtoonkasi: 🆕#ctDNA🩸🧬kinetics @CCR_AACR. 💡Imp to realize that ctDNA is a dynamic marker. Being ctDNA➕doesn’t mean that 💯 recurrence.…
RT @pashtoonkasi: 🆕#ctDNA🩸🧬kinetics @CCR_AACR. 💡Imp to realize that ctDNA is a dynamic marker. Being ctDNA➕doesn’t mean that 💯 recurrence.…
RT @pashtoonkasi: 🆕#ctDNA🩸🧬kinetics @CCR_AACR. 💡Imp to realize that ctDNA is a dynamic marker. Being ctDNA➕doesn’t mean that 💯 recurrence.…
RT @pashtoonkasi: 🆕#ctDNA🩸🧬kinetics @CCR_AACR. 💡Imp to realize that ctDNA is a dynamic marker. Being ctDNA➕doesn’t mean that 💯 recurrence.…
RT @pashtoonkasi: 🆕#ctDNA🩸🧬kinetics @CCR_AACR. 💡Imp to realize that ctDNA is a dynamic marker. Being ctDNA➕doesn’t mean that 💯 recurrence.…
RT @pashtoonkasi: 🆕#ctDNA🩸🧬kinetics @CCR_AACR. 💡Imp to realize that ctDNA is a dynamic marker. Being ctDNA➕doesn’t mean that 💯 recurrence.…
RT @pashtoonkasi: 🆕#ctDNA🩸🧬kinetics @CCR_AACR. 💡Imp to realize that ctDNA is a dynamic marker. Being ctDNA➕doesn’t mean that 💯 recurrence.…
RT @pashtoonkasi: 🆕#ctDNA🩸🧬kinetics @CCR_AACR. 💡Imp to realize that ctDNA is a dynamic marker. Being ctDNA➕doesn’t mean that 💯 recurrence.…
RT @pashtoonkasi: 🆕#ctDNA🩸🧬kinetics @CCR_AACR. 💡Imp to realize that ctDNA is a dynamic marker. Being ctDNA➕doesn’t mean that 💯 recurrence.…
RT @pashtoonkasi: 🆕#ctDNA🩸🧬kinetics @CCR_AACR. 💡Imp to realize that ctDNA is a dynamic marker. Being ctDNA➕doesn’t mean that 💯 recurrence.…
RT @pashtoonkasi: 🆕#ctDNA🩸🧬kinetics @CCR_AACR. 💡Imp to realize that ctDNA is a dynamic marker. Being ctDNA➕doesn’t mean that 💯 recurrence.…
RT @pashtoonkasi: 🆕#ctDNA🩸🧬kinetics @CCR_AACR. 💡Imp to realize that ctDNA is a dynamic marker. Being ctDNA➕doesn’t mean that 💯 recurrence.…
RT @pashtoonkasi: 🆕#ctDNA🩸🧬kinetics @CCR_AACR. 💡Imp to realize that ctDNA is a dynamic marker. Being ctDNA➕doesn’t mean that 💯 recurrence.…
RT @pashtoonkasi: 🆕#ctDNA🩸🧬kinetics @CCR_AACR. 💡Imp to realize that ctDNA is a dynamic marker. Being ctDNA➕doesn’t mean that 💯 recurrence.…
RT @pashtoonkasi: 🆕#ctDNA🩸🧬kinetics @CCR_AACR. 💡Imp to realize that ctDNA is a dynamic marker. Being ctDNA➕doesn’t mean that 💯 recurrence.…
RT @pashtoonkasi: 🆕#ctDNA🩸🧬kinetics @CCR_AACR. 💡Imp to realize that ctDNA is a dynamic marker. Being ctDNA➕doesn’t mean that 💯 recurrence.…
RT @pashtoonkasi: 🆕#ctDNA🩸🧬kinetics @CCR_AACR. 💡Imp to realize that ctDNA is a dynamic marker. Being ctDNA➕doesn’t mean that 💯 recurrence.…
RT @pashtoonkasi: 🆕#ctDNA🩸🧬kinetics @CCR_AACR. 💡Imp to realize that ctDNA is a dynamic marker. Being ctDNA➕doesn’t mean that 💯 recurrence.…
RT @pashtoonkasi: 🆕#ctDNA🩸🧬kinetics @CCR_AACR. 💡Imp to realize that ctDNA is a dynamic marker. Being ctDNA➕doesn’t mean that 💯 recurrence.…
🆕#ctDNA🩸🧬kinetics @CCR_AACR. 💡Imp to realize that ctDNA is a dynamic marker. Being ctDNA➕doesn’t mean that 💯 recurrence. Earlier studies only looked at post-op MRD in those who didn’t get any adjuvant (all recurred). If➕➡️➖, good sign. @OncoAlert https://
RT @TarazonaNoelia: 📢Just out: our paper based on liquid biopsy in stage III CRC🩸🧪 ¨ctDNA detection and growth rate assessment provides uni…
RT @TarazonaNoelia: 📢Just out: our paper based on liquid biopsy in stage III CRC🩸🧪 ¨ctDNA detection and growth rate assessment provides uni…
RT @Thalcin: The promise of ctDNA in the clinical setting! Looking forward to participation of @RIMUHC1 to CO.29 by @CDNCancerTrials an…
RT @TarazonaNoelia: 📢Just out: our paper based on liquid biopsy in stage III CRC🩸🧪 ¨ctDNA detection and growth rate assessment provides uni…
PubMed_ Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of recurrences https://t.co/G3C54XodZh
New article: Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of recurrences https://t.co/ETEdfxoqIZ #breastcancer #oncology https://t.co/
New article: Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of recurrences https://t.co/N6eFEJjgky #colorectalcancer #oncology https://t
RT @TarazonaNoelia: 📢Just out: our paper based on liquid biopsy in stage III CRC🩸🧪 ¨ctDNA detection and growth rate assessment provides uni…
RT @TennaVesterman: What can serial circulating tumor DNA monitoring tell us about recurrence in colorectal cancer patients? A whole lot!…
RT @TarazonaNoelia: 📢Just out: our paper based on liquid biopsy in stage III CRC🩸🧪 ¨ctDNA detection and growth rate assessment provides uni…
RT @AndresC27622123: Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of…
RT @AndresC27622123: Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of…
RT @AndresC27622123: Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of…
RT @AndresC27622123: Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of…
RT @oncologician: Congratulations ! The Hazards ratio of CtDNA positive patients after stagIII colorectal cancer surgery was 7.0 and if CtD…
RT @TarazonaNoelia: 📢Just out: our paper based on liquid biopsy in stage III CRC🩸🧪 ¨ctDNA detection and growth rate assessment provides uni…
RT @TarazonaNoelia: 📢Just out: our paper based on liquid biopsy in stage III CRC🩸🧪 ¨ctDNA detection and growth rate assessment provides uni…
RT @AndresC27622123: Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of…
The promise of ctDNA in the clinical setting! Looking forward to participation of @RIMUHC1 to CO.29 by @CDNCancerTrials and @GICancer https://t.co/fj83uq9Gkk
RT @AndresC27622123: Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of…
RT @TarazonaNoelia: 📢Just out: our paper based on liquid biopsy in stage III CRC🩸🧪 ¨ctDNA detection and growth rate assessment provides uni…
RT @AndresC27622123: Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of…
Congratulations ! The Hazards ratio of CtDNA positive patients after stagIII colorectal cancer surgery was 7.0 and if CtDNA positive after post op chemo then HR- 50% .Have you ever seen these kind of HR’s ? @pashtoonkasi @KhandareJayant @UmutDisel
RT @AndresC27622123: Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of…
Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of recurrences https://t.co/o5RJil3RSo
RT @TarazonaNoelia: 📢Just out: our paper based on liquid biopsy in stage III CRC🩸🧪 ¨ctDNA detection and growth rate assessment provides uni…
RT @TennaVesterman: What can serial circulating tumor DNA monitoring tell us about recurrence in colorectal cancer patients? A whole lot!…
RT @TarazonaNoelia: 📢Just out: our paper based on liquid biopsy in stage III CRC🩸🧪 ¨ctDNA detection and growth rate assessment provides uni…
RT @TennaVesterman: What can serial circulating tumor DNA monitoring tell us about recurrence in colorectal cancer patients? A whole lot!…
Interested in monitoring colorectal cancer patients using serial ctDNA detection? Read more below in the newly published CCR paper from our group. Great work @TennaVesterman, @ClausLindbjerg, @amanda_fbj and co-authors!
RT @AndresC27622123: Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of…
RT @AndresC27622123: Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of…
RT @TarazonaNoelia: 📢Just out: our paper based on liquid biopsy in stage III CRC🩸🧪 ¨ctDNA detection and growth rate assessment provides uni…
RT @TarazonaNoelia: 📢Just out: our paper based on liquid biopsy in stage III CRC🩸🧪 ¨ctDNA detection and growth rate assessment provides uni…
RT @AndresC27622123: Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of…
RT @TarazonaNoelia: 📢Just out: our paper based on liquid biopsy in stage III CRC🩸🧪 ¨ctDNA detection and growth rate assessment provides uni…
RT @TennaVesterman: What can serial circulating tumor DNA monitoring tell us about recurrence in colorectal cancer patients? A whole lot!…
RT @TarazonaNoelia: 📢Just out: our paper based on liquid biopsy in stage III CRC🩸🧪 ¨ctDNA detection and growth rate assessment provides uni…
RT @TarazonaNoelia: 📢Just out: our paper based on liquid biopsy in stage III CRC🩸🧪 ¨ctDNA detection and growth rate assessment provides uni…
RT @TarazonaNoelia: 📢Just out: our paper based on liquid biopsy in stage III CRC🩸🧪 ¨ctDNA detection and growth rate assessment provides uni…
RT @AndresC27622123: Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of…
RT @TarazonaNoelia: 📢Just out: our paper based on liquid biopsy in stage III CRC🩸🧪 ¨ctDNA detection and growth rate assessment provides uni…
RT @TarazonaNoelia: 📢Just out: our paper based on liquid biopsy in stage III CRC🩸🧪 ¨ctDNA detection and growth rate assessment provides uni…
RT @TarazonaNoelia: 📢Just out: our paper based on liquid biopsy in stage III CRC🩸🧪 ¨ctDNA detection and growth rate assessment provides uni…
RT @AndresC27622123: Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of…
RT @TarazonaNoelia: 📢Just out: our paper based on liquid biopsy in stage III CRC🩸🧪 ¨ctDNA detection and growth rate assessment provides uni…
RT @TarazonaNoelia: 📢Just out: our paper based on liquid biopsy in stage III CRC🩸🧪 ¨ctDNA detection and growth rate assessment provides uni…
RT @TennaVesterman: What can serial circulating tumor DNA monitoring tell us about recurrence in colorectal cancer patients? A whole lot!…
RT @AndresC27622123: Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of…
RT @TarazonaNoelia: 📢Just out: our paper based on liquid biopsy in stage III CRC🩸🧪 ¨ctDNA detection and growth rate assessment provides uni…
RT @AndresC27622123: Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of…
RT @ClausLindbjerg: Great work and excellent collaboration
RT @AndresC27622123: Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of…
RT @TarazonaNoelia: 📢Just out: our paper based on liquid biopsy in stage III CRC🩸🧪 ¨ctDNA detection and growth rate assessment provides uni…
RT @TarazonaNoelia: 📢Just out: our paper based on liquid biopsy in stage III CRC🩸🧪 ¨ctDNA detection and growth rate assessment provides uni…
RT @TennaVesterman: What can serial circulating tumor DNA monitoring tell us about recurrence in colorectal cancer patients? A whole lot!…
RT @AndresC27622123: Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of…
Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of recurrences https://t.co/J8E0Pkdfj2
RT @TarazonaNoelia: 📢Just out: our paper based on liquid biopsy in stage III CRC🩸🧪 ¨ctDNA detection and growth rate assessment provides uni…
RT @TarazonaNoelia: 📢Just out: our paper based on liquid biopsy in stage III CRC🩸🧪 ¨ctDNA detection and growth rate assessment provides uni…
📢Just out: our paper based on liquid biopsy in stage III CRC🩸🧪 ¨ctDNA detection and growth rate assessment provides unique opportunities for guiding decision-making¨ @TennaVesterman @ClausLindbjerg @AndresC27622123 @NateraOncology @incliva_iis 👇 https://
RT @TennaVesterman: What can serial circulating tumor DNA monitoring tell us about recurrence in colorectal cancer patients? A whole lot!…
Great work and excellent collaboration
@TennaVestermann and coworkers have published a study on how ctDNA can help guide the treatment decisions for colorectal cancer patients in the future. Find the study here: https://t.co/ORdhoGqRmS @cancer_dk @KnaekCancer
RT @TennaVesterman: What can serial circulating tumor DNA monitoring tell us about recurrence in colorectal cancer patients? A whole lot!…
RT @TennaVesterman: What can serial circulating tumor DNA monitoring tell us about recurrence in colorectal cancer patients? A whole lot!…
What can serial circulating tumor DNA monitoring tell us about recurrence in colorectal cancer patients? A whole lot! Read more in our latest paper in @CCR_AACR: https://t.co/byPTYR8ZXR Thanks @TarazonaNoelia @amanda_fbj @AndresC27622123 @ClausLindbjer